Affordable Access

Publisher Website

Pharmacokinetics of quinapril in patients with renal dysfunction

Authors
Journal
Current Therapeutic Research
0011-393X
Publisher
Elsevier
Publication Date
Volume
54
Issue
6
Identifiers
DOI: 10.1016/s0011-393x(05)80696-4
Disciplines
  • Pharmacology

Abstract

Abstract The pharmacokinetic properties of quinapril were evaluated in 6 hypertensive patients with normal renal function (group A), 4 hypertensive patients with mild-to-moderate renal dysfunction (group B), and 3 hypertensive patients with severe renal dysfunction (group C). Assessments were made after patients received a single oral 10-mg dose of quinapril and after they received 8 consecutive days of treatment. The peak drug level and the area under the curve for quinaprilat (the active metabolite of quinapril) were 2 to 4 times higher in group C than in group A after 8 days of treatment; this difference was statistically significant. A significant correlation between the area under the curve and serum creatinine levels was observed after the single dose and after 8 days of treatment. Based on our results, we recommend that patients with renal dysfunction receive only half the dose of quinapril administered to patients with normal renal function.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Pharmacokinetics and pharmacodynamics of quinapril...

on European Journal of Clinical P... 1993

The pharmacokinetics of quinapril and its active m...

on Journal of clinical pharmacolo... April 1992

Quinapril hydrochloride effects on renal function...

on Cardiovascular drugs and thera... April 1994

The pharmacokinetics and pharmacodynamics of quina...

on British journal of clinical ph... August 1990
More articles like this..